Bifogade filer
PDF
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
- The latest circVec 3.0 generation of its circular RNA therapeutic platform technology has now been validated in multiple vector formats
- New delivery data demonstrates efficient delivery to the spleen, opening novel circVec opportunities in cell therapy
- Rich pipeline of upcoming R&D milestones, including several existing and new research collaborations
- Presentation of 2024 financial results, including ongoing activities to strengthen Circio's financial position
Oslo, Norway 26 March 2025 - Circio Holding ASA (OSE: CRNA), a biotechnology company developing powerful circular RNA technology for next generation nucleic acid medicine, is hosting a live webcast at 10:00am CET today Wednesday 26 March 2025. In the webcast, Circio management will present the 2024 financial results, provide a general corporate update and present the latest developments for the circVec platform technology.
The presentation will show the advantages and potential of Circio's newest circVec 3.0 generation and ongoing activities to validate its performance in therapeutic vector formats. In addition, recent systemic LNP-delivery data will be discussed that demonstrate robust and durable circVec expression in the spleen, far outperforming equivalent mRNA-vectors. This important finding creates potential therapeutic opportunities for the circVec technology in new areas, such as cell therapy.
"Circio's latest results showing efficient and specific LNP-delivery to the spleen are very promising and have the potential to open up novel opportunities for the circVec platform in cell and immune therapies," said Dr. Erik D Wiklund, CEO of Circio. "We now have a broad set of ongoing experiments, both internally and through several external research collaborations, that are generating multiple important in vivo data read outs during Q2. The performance of circVec 3.0-AAV constructs is of particular importance, with the potential to generate substantial near-term partnering interest."
A summary of the financial results for 2024 and corporate outlook for 2025 will also be covered in the presentation. During 2024, Circio completed both a rights issue and private placement, strengthening the financial situation and shareholder base of the company. In parallel, substantial cost saving measures were implemented, thereby extending the cash runway and enabling maximized R&D progress on a low cost base. A multi-pronged strategy is being pursued to secure long-term funding, including extension of the Atlas financing commitment, fundraising and structural and business development transactions.
Presenters:
CEO Dr. Erik Digman Wiklund
CFO Dr. Lubor Gaal
Time: 10:00 CET on 26 March 2025
click here to access the Teams webcast
Meeting ID: 392 868 593 190
Passcode: Mn7uS2qQ
Participate by phone:
+47 21402155
Phone conference ID: 394 288 903#
A recording of the webcast will be made available on the Circio webpage